伊布替尼致房颤归因于抑制C端Src激酶
本研究通过小鼠电生理实验、化学蛋白质组学分析、遗传小鼠模型及药物警戒数据库查询,探究伊布替尼致房颤的机制。结果显示,伊布替尼处理4周的小鼠出现可诱发的房颤、左房扩大、心肌纤维化和炎症,该效应在Bruton酪氨酸激酶缺陷小鼠中重现,但在使用更特异性BTK抑制剂阿卡替尼的小鼠中未重现,提示房颤为脱靶效应。化学蛋白质组学筛选将CSK(C端Src激酶)确定为最强候选靶点,心脏特异性Csk敲除小鼠表现出与伊布替尼处理相似的表型。VigiBase分析证实,抑制CSK的激酶抑制剂与房颤报告增加相关,报告比值比为8.0(95%CI 7.3-8.7;P<0.0001)。结论:CSK抑制是伊布替尼导致房颤的机制。
要点
- 伊布替尼致房颤为脱靶效应,与BTK抑制无关
- CSK抑制是伊布替尼诱导房颤的关键机制
- 抑制CSK的激酶抑制剂与房颤报告增加相关,报告比值比8.0
核心结论
- CSK抑制是伊布替尼导致房颤的机制。
研究设计与样本
- 小鼠电生理实验:伊布替尼处理4周评估房颤可诱发性。
- 化学蛋白质组学分析心脏裂解物鉴定候选靶点。
- 遗传小鼠模型及额外药理学实验验证候选靶点。
- 查询药物警戒数据库VigiBase分析激酶抑制剂与房颤报告关联。
主要发现
- 伊布替尼处理4周小鼠出现可诱发性房颤、左房扩大、心肌纤维化和炎症。
- BTK缺陷小鼠重现上述效应,而阿卡替尼处理4周小鼠未重现,提示房颤为脱靶效应。
- 化学蛋白质组学筛选将CSK确定为伊布替尼诱导房颤的最强候选靶点。
- 心脏特异性Csk敲除小鼠出现房颤增加、左房扩大、纤维化和炎症,表型与伊布替尼处理相似。
- VigiBase分析显示抑制CSK的激酶抑制剂与房颤报告增加相关,报告比值比8.0(95%CI 7.3-8.7;P<0.0001)。
临床怎么用
- 使用伊布替尼时需监测房颤发生,尤其关注CSK抑制相关脱靶效应。
- 对于需BTK抑制的患者,可考虑选用脱靶效应更少的BTK抑制剂如阿卡替尼以降低房颤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood. METHODS: We performed electrophysiology studies on mice treated with ibrutinib to assess inducibility of AF. Chemoproteomic analysis of cardiac lysates identified candidate ibrutinib targets, which were further evaluated in genetic mouse models and additional pharmacological experiments. The pharmacovigilance database, VigiBase, was queried to determine whether drug inhibition of an identified candidate kinase was associated with increased reporting of AF. RESULTS: We demonstrate that treatment of mice with ibrutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflammation. This effect was reproduced in mice lacking Bruton tyrosine kinase, but not in mice treated with 4 weeks of acalabrutinib, a more specific Bruton tyrosine kinase inhibitor, demonstrating that AF is an off-target side effect. Chemoproteomic profiling identified a short list of candidate kinases that was narrowed by additional experimentation leaving CSK (C-terminal Src kinase) as the strongest candidate for ibrutinib-induced AF. Cardiac-specific Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phenocopying ibrutinib treatment. Disproportionality analyses in VigiBase confirmed increased reporting of AF associated with kinase inhibitors blocking Csk versus non-Csk inhibitors, with a reporting odds ratio of 8.0 (95% CI, 7.3-8.7; P<0.0001). CONCLUSIONS: These data identify Csk inhibition as the mechanism through which ibrutinib leads to AF. Registration: URL: https://ww.clinicaltrials.gov; Unique identifier: NCT03530215.
引用
- Xiao L, Salem JE, Clauss S, et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 2020. PMID: 33092403. doi:10.1161/CIRCULATIONAHA.120.049210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。